Renal Cell Carcinoma (RCC) Clinical Trial
Official title:
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
| Completed |
NCT03955393 -
FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
|
||
| Completed |
NCT02903914 -
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
| Completed |
NCT00557609 -
Phase 2 Study in Patients With MiT Tumors
|
Phase 2 | |
| Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT01235962 -
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
|
Phase 3 | |
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT00199888 -
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
|
Phase 1 | |
| Completed |
NCT03538028 -
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT03549000 -
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
|
Phase 1 | |
| Completed |
NCT02178722 -
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05410509 -
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
|
N/A | |
| Completed |
NCT02646748 -
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04187872 -
LITT and Pembrolizumab in Recurrent Brain Metastasis
|
Phase 1 | |
| Terminated |
NCT00520533 -
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT04375150 -
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
|
||
| Terminated |
NCT03311334 -
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05909995 -
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
|
Phase 1 | |
| Completed |
NCT01666353 -
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
|
Early Phase 1 |